Breaking News

2 Biotech Beauties Poised To Breakout

By John PersinosStock MarketsNov 12, 2016 03:16AM ET
2 Biotech Beauties Poised To Breakout
By John Persinos   |  Nov 12, 2016 03:16AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

The biggest profits can be made not from investing in Big Pharma companies, but from smaller-cap stocks in the biotech sector. We’ve pinpointed two small biotech companies poised to break out: VBI Vaccines Inc (NASDAQ:VBIV) and InMed Pharmaceuticals Inc (SNX:IN).

VBI’s vaccines are unique because they harness a proprietary technology created by the company, called an enveloped virus-like particle (VLP). This allows efficient and effective delivery of the vaccine by mimicking the ways the viruses travel through the body’s systems.

VBI is currently developing two vaccines for diseases that have high demand for prevention: hepatitis B and the cytomegalovirus (similar to Zika).

But VBI isn’t just a shot in the dark, floating alone in the scary biotech space. There are some big names standing behind the small-cap ($111 million) company. Perceptive Advisors’ biotech-focused fun, the Perceptive Life Sciences Fund, which is led by CEO Joseph Edelman, has bought a sizeable stake, as has Arch Ventures, helmed by Robert Nelsen, and Opko Health Inc (NASDAQ:OPK), with CEO Dr. Phillip Frost.

These are biotech investors with impressive track records – from Edelman’s stunning 5,000% play on Sarepta Therapeutics Inc (NASDAQ:SRPT) to Nelson’s early bid on Juno Therapeutic (NASDAQ:JUNO), to Frost’s own IVAX, a vaccination company that he sold to Teva Pharmaceutical Industries (NYSE:TEVA) for more than $7 billion.

VBI’s CEO, Jeff Baxter, is also in a good place to lead his company to success. He has a long and impressive resume that includes stints at Glaxo, as well as at Unilever (LON:ULVR) and British American Tobacco (LON:BATS) .

With its impressive roster of financial backers, as well as a seasoned exec, VBI is the best small-cap play for investors looking to substantially profit from the growing vaccine market.

InMed is a mere penny stock – currently priced around 15 cents per share – but it packs a wallop. The company has created its own proprietary biosynthesis drug development platform that derives cannabinoids from plants in an unprecedentedly cost effective and efficient manner. This process can help the company develop treatments at a faster pace than any other medical marijuana treatment-maker.

InMed’s chief medical officer, Dr. Ado Muhammed, formerly served as associate medical director at mid-cap marijuana biotech GW Pharmaceuticals Plc (NASDAQ:GWPH) and is one of the few scientists who has had clinical experience with a cannabinoid-based drug that has already been approved by the FDA (Sativex, GM’s blockbuster MS treatment).

InMed is developing therapies for conditions such as epidermolysis bullosa (EB, a serious pediatric skin disease), as well as glaucoma. There’s the potential for as much as $1 billion for a successful EB drug – currently, there’s no therapy on the market.

That would give InMed and its investors some incredible profits, as well as making the stock ripe for the picking by any Big Pharma player.

The most exciting biotech gains are currently – and will continue to be – made in from marijuana-based treatments. As pot picks up in pharmaceutical popularity, prepare your portfolio for sky-high profits.

2 Biotech Beauties Poised To Breakout

Related Articles

2 Biotech Beauties Poised To Breakout

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Are you sure you want to delete this chart?
Write your thoughts here
Replace the attached chart with a new chart ?
Post also to:
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Arun Lama
Arun Lama Dec 20, 2016 6:18AM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Having launched Sci-B-Vac commercially in 15 countries and having other vaccine candidates in the pipeline, VBI vaccine is considered as the under the radar company by the analysts. The vaccine candidates that are in the pipeline include- CMV, GBM, MB, Zika, and RSV. .InMed has two products in the pipeline which are- INM-7 and INM-085. INM-7 is for the treatment of Epidermolysis Bullosa, and INM-085 is for the treatment of Glaucoma. Both of these products are expected to have billion dollars global market if they ever get commercialized. .
0 0
Robert Stewart
Robert Stewart Nov 22, 2016 4:33PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Investing in small cap companies is the best way to compound our money. Studies have shown that small caps companies beat the large cap companies in the long run. It’s because small caps have large growth potential while the matured companies have limited growth. Small caps investors choose potential over stability. Small caps are not stable as large caps are because small caps companies keep bringing new products in the market and the sales might fluctuate heavily. In the case of large caps like Microsoft, they are already a branded company, they have stable business.. .Small caps are rarely covered by the analysts but I’m glad you wrote about it. I believe that fortunes can be made in small caps not in matured companies. So, I’m quite interested to know more about VBI and InMed. Thanks for sharing. ..I would love to invest in companies that are related to marijuana based products because I think it’s cool. Happy investing. ..
0 0
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Post 1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email